Your browser doesn't support javascript.
loading
Time to onset and duration of botulinum toxin efficacy in movement disorders.
Ledda, Claudia; Artusi, Carlo Alberto; Tribolo, Antonella; Rinaldi, Domiziana; Imbalzano, Gabriele; Lopiano, Leonardo; Zibetti, Maurizio.
Afiliação
  • Ledda C; Department of Neuroscience "Rita Levi Montalcini", University of Turin, Via Cherasco 15, 10126, Turin, Italy.
  • Artusi CA; Neurology 2 Unit, A.O.U. Città della Salute e della Scienza di Torino, Corso Bramante 88, 10126, Turin, Italy.
  • Tribolo A; Department of Neuroscience "Rita Levi Montalcini", University of Turin, Via Cherasco 15, 10126, Turin, Italy. caartusi@gmail.com.
  • Rinaldi D; Neurology 2 Unit, A.O.U. Città della Salute e della Scienza di Torino, Corso Bramante 88, 10126, Turin, Italy. caartusi@gmail.com.
  • Imbalzano G; Department of Neuroscience "Rita Levi Montalcini", University of Turin, Via Cherasco 15, 10126, Turin, Italy.
  • Lopiano L; Neurology 2 Unit, A.O.U. Città della Salute e della Scienza di Torino, Corso Bramante 88, 10126, Turin, Italy.
  • Zibetti M; Dipartimento di Neuroscienze, Salute Mentale e Organi di Senso, Sapienza Università di Roma, Via di Grottarossa, 1035, 00189, Rome, Italy.
J Neurol ; 269(7): 3706-3712, 2022 Jul.
Article em En | MEDLINE | ID: mdl-35113259
ABSTRACT

BACKGROUND:

Botulinum toxin (BoNT) is a valuable treatment in movement disorders; however, time to onset and duration of efficacy may widely differ among patients. We aimed to clarify the impact of main demographic and clinical features on time to onset and duration of BoNT efficacy.

METHODS:

We analyzed time-to-onset and duration of BoNT efficacy in 186 consecutive patients treated with BoNT for blepharospasm, cervical dystonia, facial hemispasm, oromandibular dystonia, limb dystonia, and sialorrhea due to Parkinsonism. The following factors were considered as potential efficacy predictors doses and types of toxin, sex, age, years of treatment, and clinical condition. Kruskall-Wallis, Spearman correlation, and multivariate linear regression were used for statistical analysis.

RESULTS:

The average time to onset was 6.7 ± 5 days and duration of BONT efficacy 78.5 ± 28.4 days. Both time to onset and duration of efficacy were correlated with BoNT doses (p 0.007 and p 0.02). The multiple regression analysis showed that sex, age, years of BoNT treatment, doses, type of toxin, and clinical condition significantly predicted time to onset (F(11, 171) = 2.146, p 0.020) with age being the strongest predictor (p 0.004). The same model explained 20.1% of the variance of duration of BoNT efficacy, showing a significant prediction of the outcome (F(11, 164) = 3.754, p < 0.001), with doses (p < 0.001), type of toxin (p 0.017), and clinical condition (p < 0.001) being the strongest predictors.

CONCLUSION:

Our findings suggest that age, type of toxin, clinical condition and especially doses may account for the variability of BoNT efficacy in terms of time to onset and duration.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sialorreia / Torcicolo / Blefarospasmo / Toxinas Botulínicas Tipo A / Transtornos dos Movimentos / Fármacos Neuromusculares Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Humans Idioma: En Revista: J Neurol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sialorreia / Torcicolo / Blefarospasmo / Toxinas Botulínicas Tipo A / Transtornos dos Movimentos / Fármacos Neuromusculares Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Humans Idioma: En Revista: J Neurol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália